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Murine myeloma proteins with different specificities are produced by induction of 
plasmacytomas in BALB/c and NZB mice after intraperitoneal injection of mineral 
oil or solid plastic material (1-7). Their specificities have been characterized by their 
ability  to  react  with  various  antigens  such  as  dextran,  levan, fl(1---~6)-D-galactan, 
nucleic acid, pneumococcal C  polysaccharide, serum lipoprotein, dinitrophenyl-sub- 
stituted  protein,  glycoproteins  with  nonreducing  N-acetyl-D-glucosamine  (8)  and 
proteins containing artificially introduced N-acetyl-D-glucosamine residues  (8).  The 
specificities and combining site sizes of BALB/c and NZB myeloma antidextrans have 
been extensively studied by quantitative precipitin inhibition assays (9-12) and have 
been confirmed by measurements of their association constants by equilibrium dialysis 
(13,  14),  fluorescence quenching (13,  15),  and affinity electrophoresis (16,  17).  The 
cavity-type combining site of the BALB/c anti-dextran W3129 specific for terminal 
nonreducing chains of a(1---~6)-linked  dextrans is most complementary to isomalto- 
pentaose  (11,  13,  15,  16),  whereas  the  groove-type combining  sites  of BALB/c 
QUPC52 antidextran specific for internal chains of a(1--~6)-linked glucoses was most 
complementary to isomaltohexaose (11,  13). NZB antidextrans PC3658 and PC3936 
are also specific for internal a(1--~6)  chains, although their combining site sizes are 
somewhat uncertain (12).  With BALB/c myeloma antidextrans specific for a(1---~3)- 
linked glucose, nigerotriose showed the greatest complementarity with UPC102 and 
MOPC 104E (9,  11), whereas nigeropentaose was best with J558 (10). 
In the present investigation, the immunochemical specificity of the combining site 
of CAL20 TEPC 1035, an IgG2b myeloma protein, reactive with dextrans having high 
proportions of a(1--)3)  linkages has been studied and has also been compared with 
murine myeloma antidextrans reported previously. It has a combining site that differs 
from those of all other antidextrans studied. 
Materials and Methods 
Myeloma Proteins and Antiserum.  CAL20 TEPC1035 was induced with Pristane (2,6,10,14- 
tetramethylpentadecane; 268 mol wt) by the method of Anderson and Potter (18) in a CAL20 
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mouse.  CAL20 is an  Ig BALB/c congenic strain  that  bears  the AL/N allotype locus  (19). 
CAL20 TEPC1035 was typed as an IgG2b,x immunoglobulin by immunoelectrophoresis. The 
tumor  was  transplanted  in  (BALB/c  ×  DBA/2)F1  hybrid  mice  for production  of ascites. 
Myeloma proteins J558  (IgA) MOPC104E  (IgM)  and  UPC102  (IgA)  have been  described 
previously (9-11 ). Rabbit antiserum (serum 895) to DGlcot  (1--,6) nGlca (1--.4) nGlca (1---4) DGLc 
was preipared by immunization with the oligosaccharide coupled to keyhole limpet hemocyanin 
(KLH)  via the phenethylamine-isothiocyanate derivative; the antigen used for testing was the 
oligosaccharide coupled to bovine serum albumin (BSA) (20, 21). Both antiserum and antigen 
were kindly provided by Dr. David A. Zopf of the National Institutes of Health, Bethesda, Md. 
(NIH). The oligosaccharide was coupled to BSA for use as antigen  by reacting with fl-(p- 
aminophenylethylamine)  forming the  N-alkylglycoside; this  was reduced  with  NaBH4 and 
converted to the isothiocyanate .with  thiophosgene and  coupled to BSA.  It contained  four 
oligosaccharide units per molecule BSA. It will  be referred to as panosyl-a(1--*4)DGlcckNCS 
BSA. Isomaltose oligosaccharides coupled to BSA by bromine oxidation followed by the mixed 
anhydride reaction were (22) also available. 
Dextrans.  The dextrans used in the present study have been described previously (23-30). 
The proportions of a(1---~6), a(1--*3)-like,  and a(1--*4)-like  linkages  in the dextrans used are 
summarized in Table I according to the previous reports (24-26). The L-fractions from dextrans 
B1355, B1498, and B1501 were kindly provided by Dr. M. E. Slodki (Fermentation Laboratory, 
United States Department  of Agriculture, Peoria, Ill.).  Dextran B 742S was the preparation 
previously denoted as C3R. 
Mono- and Oligosaccharides.  Glucose, methyl a-D-glucoside, methyl-/~-D-glucoside,  trehalose, 
cellobiose,  gentiobiose, kojibose,  panose, isomaltose (IM2), isomaltotriose (IM3), isomaltopen- 
taose (IM5), isomaltohexaose (IM6), isomaltoheptaose (IM7), nigerose (N2), nigerotriose (N3), 
nigerotetraose  (N4),  nigeropentaose  (N5),  nigerohexa-heptaose  (N6,7),  maltose  (M2),  malto- 
triose (M3), maltotetraose (M4), maitopentaose (M5), maltohexaose (M6), and maltoheptaose 
(M7), and branched oligosaccharides whose structures are shown in Fig. 1 have been described 
previously (10,  11,  17, 27, 28). Isopanosyla(1--*4)isopanose isolated from pullulan was kindly 
provided by Dr.  T.  Sawai,  Aichi Kyoiku University and  three  trisaccharides:  DGlca(1---~6)- 
DGlca(1--*3)oGlc,  DGlcot(1--*3)DGlca(1-*6)DGlc,  andDGlca(1-*2)DGlca(1--*6)DGlc  (29) and 
a  pentasaccharide  DGIca(1.-*2)DGIca(1-*6)DGlca(1--*6)DGIca(1--*6)DGIc  from  Dr.  M. 
Torii,  Osaka  University,  Osaka,  Japan  (31).  A  tetrasaccharide  rg31ca(1--*6)DGlca(1-*4)- 
DGlca(1--*4)DGIc was a  gift of Dr.  A.  Lundblad,  University of Lund,  Sweden through Dr. 
David Zopf. 
Immunochemicul Assay.  Quantitative  precipitin  and  precipitin  inhibition  assays  were  per- 
formed by a microprecipitin technique  (30) using a final vol of 400 #1; 6.5 #g of antibody N 
were mixed with varying amounts of antigen for quantitative precipitin assays; for quantitative 
precipitin inhibition assays, known quantities of sugars were added to 6.5 #g of antibody N and 
40 #g dextran B 1498S, an amount giving maximum precipitation in the absence of inhibitor; 
15 #g dextran B1498S,  25 #g dextran B1498S and 15 #g dextran B1355S were used with J558, 
MOPC104E, and UPC102, respectively. The mixtures were incubated at  37°C for  1 h  and 
then kept at 4°C for 1 wk. The total nitrogen content in the washed precipitate was determined 
by ninhydrin procedure (32). 
Calculation  of Association  Constant and  Free Energies.  As  reported  previously  (16,  17), the 
association constants were determined by affinity electrophoresis from the extent of retardation 
or restoration of the ligand-speeific band as a function of the concentration of inhibitor in the 
gel.  To  determine  the  association  constant  (K  a)  of dextran  to  myeloma  protein  CAL20 
TEPC1035,  dextran  at  an  appropriate  concentration  was added  to the separating  gel.  For 
determination of the association constant of inhibitor (Ki~), varying concentrations of inhibitor 
were added to the gel together with an amount of dextran B1498S (final concentration 120 #g/ 
ml) giving 50% retardation of the dextran-specific band and restoration of the mobility of the 
retarded dextran-specific band by inhibitor was measured. 3.7 #g ascitie fluid protein per tube 
was used  for determination  of K a and Kj  a. The free  energy of the oligosaccharide-myeloma 
protein interaction was calculated according to the previous reports (13, 33). 
i Abbreviations used in this paper: BSA, bovine serum albumin; K  a, association constant(s); Ki  a, association 
constant(s) of inhibition; KLH, keyhole limpet hemocyanin; NMR, nuclear magnetic resonance. 168  SPECIFICITY OF DEXTRAN-REACTIVE  SITE OF CAL20 TEPC1035 
4a-a-D-glucosylisomaltopent  aose (II/3): 
G 
Cr-.--~  G--*  G--*  Cr~  G  r 
4  4 -a-D-glucosyllsomaltohexaose  (II/4): 
G 
G--~G--*G--o  G--,G--,  G  r 
44-a-D-glucosylisomaltoheptaose  (II/5): 
G 
Cr-*  G---*C,--~  G--o  G--~  G---~  G  r 
33-0t-D-glucosylisomahopentaose  (I/4): 
G--~G--*G---*G---~Gr 
G 
34-a-u-glucosylisomaltohexaose  (I/5): 
G-*  G-.  G---*  G--~G---~  G  r 
G 
34-a-D-glucosylisomahohept  aose (I/6)  : 
G--*  G--o  G-~  C,-~  G---~G--*  G  r 
G 
FIc.  1.  Structures of branched oligosaccharides. G, D-glucopyranosyl; Gr, reducing D-glucose;  ---~, 
a-D-(1---*6) link; 1', a-9-(1----~3)  llnk; ~, a-D-(l--*4) link. Superscripts denote the substituted  glucose 
residue, counting from the reducing end. 
Results 
Quantitative Precipitin Assay.  Fig.  2  shows  the  quantitative  precipitin  curves  of 
myeloma proteins CAL20 TEPC 1035 and J558 and serum 895 with various dextrans 
and the results are summarized in Table I. As shown in Fig. 2 A, only three dextrans, 
B 1498S, B 1355S4, and B 1501 S, with high proportions of a(1---~3) linkages precipitated 
myeloma  protein  CAL20  TEPC1035.  None  of  15  other  dextrans  tested  gave  any 
precipitate. As described previously (10), the most potent precipitinogens for myeloma 
protein J558 were the same three dextrans B 1498S,  B 1355S4,  and B 1501S  (Table I). 
However, with J558, other dextrans reacted but to a  lesser extent  (10). The reactivity 
of dextrans B742S  (C3R), B1375,  and B1255  with myeloma protein J558 was two to 
three  times  less  than  those  of the  three  most  strongly  reacting  dextrans,  whereas S.  SUGII,  E.  A.  KABAT,  M.  SHAPIRO, AND  M.  POTTER  169 
TABLE  I 
Precipitating Power of Various Dextrans with Myeloma Proteins CAL20 TEPCI035, J558, and 
Serum 895 
Linkages  CAL20 
Symbol  Dextran  TEPC1035  K"  J558  895 
1----6  l---*3-1ike l---*4-11ke 
IYl  B1355S4  57  35  8  +++*  4.42 x  103  +4-+ 
[]  B1142  67  29  4  -  - 
•  B1498S  62  27  11  +++  5.02 ×  10  a  +++ 
B742S (C3R)  57  26  17  -  +4- 
V  B1501S  67  20  13  +++  3.8 x  103  +++ 
(~  Bl141  79  18  3  -  - 
[]  B1425  74  18  8  -  - 
A  B1375  81  13  6  -  4-4- 
B1351  85  11  4  -  - 
[]  N279  96  4  0  --  - 
•  B 1498L  94  6  0  -  - 
~'  B1501L  93  7  0  -  - 
[]  BI355L  95  2  3  -  - 
l~  B1399  89  0  13  -  - 
O  B1255  86  0  14  -  ++ 
®  B742L  87  0  13  -  + 
•  BI254S[E]  77  0  23  -  + 
[]  B 1299S3  65  0  35  -  ++ 
O  Pullulan  -  - 
®  Glycogen  -  - 
"0  DGlca(l-*6)  DGlca (1---4)  DGIclx  (1---4)  DGlc-  -- 
q~NCS-BSA 
IM3~NCS-BSA 
IM64~NCS-BSA 
IM2-CONH-BSA 
IM6-CONH-BSA 
II, 
+4-4- 
+4-4- 
+-1-4- 
-t-4-4- 
++4- 
+++ 
+++ 
+++ 
+++ 
++ 
++ 
+++ 
+++ 
+++ 
* +++, 6-7 pg N precipitated; ++, 2-3/~g N precipitated; +, 0.5-1/tg N precipitated; -  no N precipitated. 
dextran B 1254S  [L] and B742L were less active (Fig. 2 B  and Table I). Both myeloma 
proteins CAL20 TEPC 1035  and J558  gave no precipitation with yeast pullulan and 
rabbit  liver  glycogen  (Table  I),  nor  did  they  precipitate  with  panosyl- 
a(1---~4)DGlcNCS-BSA,  IM3-q~NCS-BSA,  IM6-q~NCS-BSA,  IM2-CONH-BSA,  and 
IM6-CONH-BSA  in precipitin assays or in gel diffusion tests, although anti-panosyl- 
a(1---~4)DGlc  (serum  895)  precipitated  well  with  panosyl-a(1---~4)DGlc~NCS-BSA, 
IM6-q~NCS-BSA, and all dextrans used as shown in Fig. 2 C. Glycogen, pullulan, and 
IM3-q~NCS-BSA precipitated poorly with anti-panosyl-a(1--*4)DGlc. 
Quantitative  Precipitin  Inhibition  Assay.  Fig.  3  and  Table  II  present  the  ability  of 
various sugars to inhibit the precipitation reaction between myeloma protein CAL20 
TEPC 1035 and dextran B 1498S. Among  various sugars tested, the best inhibitor was 
panose DGlca(1---~6)DGlca(1-*4)DGIc which was 8, 23, and 42 times more active than 
maltose,  nigerose,  and  isomahose,  respectively.  A  tetrasaccharide  DGlca(1----~6)- 
DGlca(1---~4)DGIcc~(1---~4)DGlc  was  1.5  times  more  potent  than  a  trisaccharide 
DGIca(1--*6)DGIca(I--~3)DGlc  but  3.3  times  less  active  than  panose.  Of  the  trisac- 
charides with two kinds of linkage, those with terminal nonreducing a(1--~6)-linked 170 
7 
6 
A 
~k 
a  5 
w 
-  4 
I.M  ¢w 
0.. 
Z 
ua  3 
O  n,- 
Z,  2 
SPECIFICITY OF  DKXTRAN-REACTIVE SITE  OF  CAL20  TEP(21035 
A 
V 
v 
I 
& 
V 
I 
V 
rl  m 
m 
m  I!  0 
0  ! 
0  10  20  30  40  50  60  70 
DEXTRAN ADDED (~g) 
FXG.  2 A 
FIG.  2.  Quantitative precipitin curves ofCAL20 TEP(21035  (A), J558 (B), and antiserum 895  ((2) 
with various dextrans and antigens. 50 #1 of CAL20 TEPCI035  (1:20),  50 pl ofJ558 (1:2),  and 80 
pl of serum 895 (undiluted) were used. Total vol in all cases was 400 pl. Symbols are shown in Table 
I. B1498S  and B1501S  were previously found to react comparably to B1355S  (10). 
glucose were  more active than  those  with  terminal  nonreducing  glucose linked  a- 
(1--->3), a(1--~4),  or  a(1---->2). Isopanosyla(1--*4)isopanose, DGIca(1--+4)DGIeot(1--*6)- 
DGIca(1-->4)DGIca(1--->4)DGIca(1--->6)DGIc,  was 2.85 times more potent than the iso- 
panose,  DGIca(1-->4)DGlca(1--->6)DGIc; the  latter  being  as  active  as  methyl  ¢X-V- 
glucoside.  With  a(1--->4)-linked glucosyloligosaccharides from maltose (M2)  to mal- 
toheptaose  (M7),  the order of inhibitory potency was:  maltoheptaose (M7)  =  mal- 
tohexaose (M6)  >  maltopentaose (M5)  >  maltotetraose (M4)  =  maltotriose (M3)  --- 
maltose (M2).  M7 and M6 were as potent as the tetrasaccharide DGIca(1-*6)~Iea- 
(1--->4)DGIca(1---~4)DGIc. The  a(1--->3)-linked glueosyloligosaccharides from nigerose 
(N2) to nigerohexa-heptaose (N6,N7) were about the same in inhibitory potency, but 
were about one-third as active as a(1--->4)-linked glucosyloligosaccharides. Branched 
oligosaccharides were as active or a  little less active than maltose, but more potent 
than  nigerose.  Isomaltosyloligosaccharides  were  much  less  potent  inhibitors  and 
isomaltopentaose (IM5), isomaltohexaose (IM6) and isomaltoheptaose (IM7) showed 6 
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F~c. 3.  Inhibition  by various oligosaccharides of precipitation of 50 #1 of CAL20 TEPC1035 (1: 
20) with dextran B1498S (40 #g). Total vol was 400/A. Symbols  are shown in Table II. 
44%  inhibition  at 0.5 #mol, 20%  inhibition  at 0.41  #mol and  35%  inhibition  at 0.4 
wmol, respectively. An unusual finding was that isomaltose was only one-half, nigerose 
was equally, and maltose was three times as active as methyl a-D-glucoside. Maltose, 
methyl a-D-glucoside, and isomaltose were more active than their corresponding fl- 
linked anomers such as cellobiose, methyl fl-D-glucoside, and gentiobiose. 6-O-acetyl- 
glucose was more potent  than glucose. Glucose, kojibiose, and methyl fl-D-glucoside 
gave 22% inhibition at 0.2 wmol, 20% inhibition at 0.98 #mol, and 30% inhibition at 
1.1 #mol, respectively. Trehalose showed no inhibition  up to  1.1  #mol. A  trisaccha- 
ride  DGIca(1--*2)DGlca(1---~6)oGlc  and  a  pentasaccharide  DGIcct(1---~2)DGIca- 
(1---~6)DGlcot(1----~6)DGIca(1---~6)DGlc  showed  only  15%  inhibition  at  0.36  /.tmol  and 
0.29  /~mol,  respectively.  With  myeloma proteins J558,  UPC102,  and  MOPC104E, 
nigerose was a better inhibitor than panose and maltose. Nigerose with J558, UPC 102, 
and MOPC104E showed 42% inhibition at 0.8 #mol, 55% inhibition at 0.45 #mol and 
25% inhibition  at 0.9 #mol, whereas panose gave  15% inhibition  at 0.99 #mol,  15% 
inhibition  at  0.52  #mol,  and  no  inhibition  at  up  to  0.99  /Lmol,  respectively.  With 
MOPC104E, nigerotetraose gave 75% inhibition at 0.82/~mol. 
Association Constants.  In affinity electrophoresis, the mobility of one dextran-specific 
band  in  myelorva ascitic  fluid  CAL20  TEPC1035  was  retarded  proportionally  to 
dextran  concentration  when  dextran was added  to the gel as illustrated  previously 
(16,  17).  Among  different  dextrans  used,  only  three  dextrans  which  precipitated, 
B 1498S,  B 1355S4,  and B 1501S  retarded the mobility of the dextran-specific band in 
CAL20 TEPC 1035 myeloma ascitic fluid; other dextrans, N279, B742S (C3R), B742L, 
B1425,  B1255, B1299S3,  B1375, and B1254S[L], did not show any retardation up to S.  SUGII, E.  A.  KABAT, M.  SHAPIRO, AND M.  POTTER 
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Inhibitory  Potency of Oh'gosaccharides of Precipitation  of CAL20  TEPCI 035 by Dextran B1498S 
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Curve  Relative  Symbol  Inhibitor  #tool giving 50% inhibition  No.  potency 
®  Panose nGleo~(l--*6)oGlcot(l--*4)nGlc 
-qS- nGlea (1---,6)  oGlea  (1--~4)  nGlca ( l-~4)- 
oGle 
[]  Maltoheptaose (M7) 
[~  Maltohexaose (M6) 
~t  nGlca(1----~6)  nGlca(1---* 3) nGle 
[]  Maltopentaose (M5) 
Isopanosyla(1---~4)  isopanose, DGlea- 
(1---',4)  nGlea(1---6) DGIca( 1----~4)- 
nGlea (1--4) oGlea  (1---6)  oGle 
[]  Maltotetraose (M4) 
A  Mahotriose (M3) 
•  Maltose (M2) 
•  44-a-o-glueosylisomaltohexaose  (II/4) 
[]  44-a-o-glucosylisomahohept  aose 
(II/5) 
43-a-v-glucosylisomaltopen taose 
(II/3) 
Ix.  34-O~-D-glucosylisomahohexaose  (I/5) 
"~"  oGlca(l--*  3) oGlca(1--~.6)  DGIc 
3a-a-  o-glucosylisomalt opent  aose (I/4) 
[]  34-a-o-glueosylisomaltoheptaose  (I/6) 
•  Nigerose (N2) 
•  Methyl a-D-glucoside 
'~  Isopanose 
(oGlca(1--"~4)  DGlca(1---~6)  DGlc 
O  Nigerohexa-heptaose  (N6,N7) 
Nigeropentaose (N5) 
•  Nigerotetraose  (N4) 
•  Nigerotriose  (N3) 
Cellobiose DGIe,8(1---~.4)  oGle 
&  Isomaltotriose  (IM3) 
/k  Isomaltose  (IM2) 
A  Isomaltoheptaose (IM7) 
Isomaltohexaose  (IM6) 
Isomaltopentaose (IM5) 
®  6-O-aeetyl-glucose 
0  Gentiobiose  DGIc,B(1--*6)DGIe 
X  Glucose 
Kojibiose oGlea(1-*2)DGIe 
"0 Methyl ~-D-glucoside 
[]  Trehalose DGIea( 1---*  1) DGIe 
oGlea( l---~2)oGlca(  1---*6)  oGle 
DGIca(1---'2)  DGlca( 1---*6)- 
DGIca  (1---~6)  oGlea  (1---,6)  DGlc 
l  0.015  8.0 
2  0.05  2.4 
2  0.05  2.4 
2  0.05  2.4 
0.075  1.6 
3  0.085  1.41 
4  0.12  1.0 
4  0.12  1.0 
4  0.12  1.0 
4  0.12  1.0 
4  0.12  1.0 
5  0.15  0.8 
5  0.15  0.8 
>0.15 (47% inhibition 
>0.16 (40% inhibition 
6  0.205 
6  0.205 
7  0.34 
7  0.34 
7  0.34 
7  0.36 
8  0.42 
8  0.42 
8  0.42 
8  0.5 
9  0.6 
9  0.64 
>0.4 (35% inhibition) 
>0.41  (20% inhibition) 
>0.59 (44% inhibition) 
0.84 
0.95 
22% inhibition at 0.92 #mol 
20% inhibition at 0.98 #mol 
30% inhibition at  1.i/.tmol 
No inhibition at  1.1 #tool 
15% inhibition at 0.36/~mol 
14% inhibition at 0.29 #mol 
m 
m 
0.59 
0.59 
0.35 
0.35 
0.35 
0.33 
0.29 
0.29 
0.29 
0.24 
0.20 
0.19 
0.14 
0.12 
500  #g/ml.  The  addition  of these  dextrans  at  >500  #g/ml  retarded  the  dextran- 
specific band  but  also retarded  the albumin  band  in the ascitic fluid, indicating  that, 
retardation  was nonspecific. The K a of myeloma protein CAL20 TEPC  1035 was 5.02 
×  103 ml/g  for B1498S, 4.42 ×  103 ml/g  for B1355S4,  and 3.8 ×  103 ml/g  for B1501S, 174  SPECIFICITY OF DEXTRAN-REACTIVE SITE OF CAL20 TEPCI035 
TABLE III 
Ki  a  (M -t )  of Glucosyloligosaccharides to CAL20  TEPCI035 Determined  by 
Affinity Electrophoresis 
Oligosaccharide  K?  AFo (Kcal)  Percentage 
Panose  8.19 ×  10  z  -5.32  100 
Mahotriose  1.54 ×  103  -4.34  81 
Maltose  2.34 ×  103  -4.58  86 
Methyl-a-v-glucoside  7.2 ×  10  z  -3.89  73 
respectively. On addition to the gel of dextran B 1498S together with an inhibitor, the 
retarded  dextran-specific  band  in  myeloma  ascitic  fluid  CAL20  TEPC1035  was 
restored proportionally to the inhibitor concentration as illustrated previously (16). 
The Ki" of oligosaccharide inhibitors were: 8.19 ×  l0  s M -a for panose, 1.54 ×  103 M -1 
for maltotriose,  2.34  ×  103  M -1  for maltose,  and  7.2  ×  102  M -1  for methyl a-D- 
glucoside, respectively. 
The binding energy of oligosaccharides was calculated from the Ki  a determined by 
affinity electrophoresis and are shown in Table III; maltose and mahotriose had 81 
and 86%; and methyl a-D-glucoside had 73% of the total binding energy of panose. 
Discussion 
Previously described BALB/c and NZB myeloma antidextrans have shown speci- 
ficity for either ~(1---~6)-linked  or a(1--*3)-linked oligosaccharides of glucose (9-12). 
The present  findings  demonstrate that  myeloma protein CAL20 TEPC1035  is  an 
antidextran of a different specificity from any previously described antidextran. 
Only  three  dextrans,  B1498S,  B1355S4,  and  BI501S,  with  high  proportions  of 
a(1---*3) linkages as shown in Table I precipitate myeloma protein CAL20 TEPC 1035. 
These results might suggest that myeloma protein CAL20 TEPC 1035 might be strictly 
a(1---~3) specific. However inhibition studies create problems with such an interpre- 
tation. 
The best inhibitor was panose, vGlca(1---~6)DGlca(1--*4)t~Glc  which was 2.4, 6.9, 
and  12.6 times more potent than maltose, nigerose, and isomahose, respectively. As 
shown in Table II and Fig. 3, a(1--*3)-linked glucosyloligosaccharides were much less 
active than panose and a(1--*4)-linked glucosyloligosaccharides. 
As previously reported (9-11)  the three dextrans B1498S, B1355S4, and B1501S 
were also the most potent precipitinogens for myeloma antidextrans J558, UPC102, 
and MOPC104E,  although dextrans B742S (C3R), B1255, B1299S, B1254S[L] and 
B1398 also precipitate myeloma proteins J558, UPC102, and MOPC104E but to a 
lesser extent (9-11). 
However the best inhibitors for myeloma proteins J558, UPC 102, and MOPC 104E 
were a(1--~3)-linked glucosyloligosaccharides, whereas panose and maltose were less 
active. The relative potency of panose at 50% inhibitor relative to nigerose as 1.0 on 
a molar basis was 0.105 with MOPC 104E (9); with UPC 102, 0.52 #mol panose gave 
only  15% inhibition as compared to 56% with 0.45 #mol nigerose. With J558, 0.99 
#mol  panose  gave  15%  inhibition  whereas 0.8 #mol  nigerose gave 41%  inhibition. 
Thus the specificity of the combining site of myeloma protein CAL20 TEPC1035 is 
clearly different from those of myeloma proteins J558, UPC102, and MOPC 104E. 
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charide nGIca(1---~6)DGIca(1-->4)DGIca(1-->4)DGIc,  indicating that the combining site 
size of myeloma protein CAL20 TEPC1035 is at least as large as a trisaceharide, and 
that  a  third  linkage when a(1--->4) reduces access to the combining site.  With  the 
oligosaccharides available it is not possible to decide whether inhibiting power would 
increase if the panosyl moiety were linked other than a(1---,4)  to an additional glucose. 
Thus the data only establish a minimum estimate for the combining site size. Because 
one seldom, if ever, can be certain with myeloma proteins of the specificity of the 
antigens that induce the clone, a precise definition of the complementarity of the site 
is only obtainable when all possible related oligosaccharides have been tested. 
The combining site of myeloma protein CAL20 TEPC 1035 is specific for a-linked 
glucose  because  maltose,  isomaltose,  and  methyl  a-D-glucoside  were  more  potent 
inhibitors  than  the  corresponding  fl-linked  anomers,  cellobiose,  gentiobiose,  and 
methyl fl-v-glucoside. Among a-linked trisaccharides with two kinds of linkage tested, 
those with a  terminal nonreducing a(1--*6) linkage were more inhibitory than those 
with either a(1---~3), a(1--->4), or a(1---~2) linkages because panose and the trisaccharide 
vGlca(1--*6)vGlca(1---~3)I~Glc  were  more  specific  for  myeloma  protein  CAL20 
TEPC1035 than the corresponding isomers, isopanose and vGlca(l--*3)oGlea(1-->6)- 
vGlc, respectively. The linkage of the second to the third sugar is thus also important 
for binding and the order of inhibitor potency was:  1---4 >  1--->3 >  1---6 as shown in 
Table II. These findings clearly show that the conformation of the combining site is 
highly specific. Inhibition tests with a(1--*4)-linked glucosyl oligosaccharides showed 
the order of inhibitory potency to be:  maltoheptaose (M7)  ffi maltohexaose (M6) > 
maltopentaose (M5)  >  maltotetraose  (M4)  ffi mahotriose (M3)  ffi maltose (M2). A 
similar order of inhibition was obtained with isomaltose oligosaccharides in inhibition 
tests with BALB/c and NZB myeloma antidextrans with groove-type sites of a(1--*6) 
specificity (11,  12). The increased potency of M7 and M6 as compared with M2 and 
M3  may  be  attributable  to  the  longer  sugar  chains  having  an  effective partial 
bivalence e.g., to their ability to interact with the site in several ways. The failure of 
CAL20 TEPC1035 to precipitate with glycogen is surprising. However, the average 
length of the a(1---~4) chains in glycogen per a(1-->6)  branch point is ~14 units (34) 
so that these would show a considerable tendency to form helices, which would not 
provide an optimal conformation for precipitation. Indeed, in inhibition studies with 
human  antidextran, 9D4,  M3,  M4,  and  M5 were equally active on a  molar basis, 
whereas M7, the smallest oligosaccharide theoretically capable of forming one turn of 
a helix was somewhat less active (35). 
In addition to these findings, the isopanosyla(1-->4) isopanose, vGlca(1--->4)DGlca- 
(1---~6)DGlca(1-->4)vGlca(1--->4)DGlca(1--*6)DGlc  was  more  potent  than  isopanose 
vGlca(1---->4)vGlca(1-*6)t~Glc. If the site was entirely groove-type, one might  have 
expected the isopanosyl a(1-->4)  isopanose to react as well as panose, the nonreducing 
terminal  DGlca(1-->4)  being outside with the internal ---->4vGlca(1--*6)vGlca(1-->4)- 
vGlca- moiety occupying the same position as panose in the site. As this was not the 
case and as the isopanosyl a(1---->4) isopanose was only as active as maltose, M3, and 
M4,  the  higher  activity  of  the  isopanosyl  a(l---->4) isopanose  as  compared  with 
isopanose  is  ascribable  to  interaction with  the  internal  maltosyl  moieties.  Panose 
would  react optimally in  the site,  whereas  M2  to M5  and  the  isopanosyl a(1--->4) 
isopanose would interact only with the groove subsite. The Ki  a of methyl a-D-glucoside 
was  7.2  ×  102 for CAL20 TEPC1035 comparable to that of 9.4 ×  10  z for myeloma 176  SPECIFICITY OF  DEXTRAN-REACTIVE SITE OF CAL20 TEPC1035 
protein  W3129  which  has  a  cavity type site complementary to  a  pentasaccharide. 
Further, this Ki  a is 600 times higher than that,  1.6 ×  10  °, for QUPC52 with a groove- 
type site complementary to a  hexasaccharide  (13).  The Ki  a of methyl a-D-glucoside 
for  CAL20  TEPC1035  was  73%  that  of panose;  in  W3129  it  was  1.5%;  and  in 
QUPC52  it was 0.23% that of IM3. Thus, the terminal nonreducing  glucose linked 
a  contributes  predominantly  to  binding  with  CAL20  TEPC1035.  These  findings 
suggest that the combining site of myeloma antidextran CAL20 TEPC1035  may be 
a partial cavity-type with the terminal nonreducing oGlc being held in three dimen- 
sions with the next two sugars in a groove. 
However, relative to methyl c~-D-glucoside,  isomaltose was only one-half as potent 
as an  inhibitor,  whereas  nigerose was equally  active, and  maltose was  about  three 
times as active. The difference between methyl a-D-glucoside and isomahose is small 
and  could  be a  consequence  of isomaltose assuming  an  unfavorable  conformation 
alone whereas  in  nigerose,  maltose,  and  panose  it  would  exist  in  a  more restricted 
conformation. 
As  shown  above,  myeloma  protein  CAL20  TEPC1035  only  precipitated  three 
dextrans with high proportions of a(1--*3)  linkages although  its combining site was 
not  most  complementary  to  a(1---~3)-linked  glucoses  and  although  a(1---*4)-linked 
glucosyloligosaccharides  show  more  affinity  for  the  combining  site  than  a(1--~3)- 
linked glucosyloligosaccharides.  Dextrans B1254S[L]  and B742L did not precipitate 
myeloma protein CAL20 TEPC1035. 
Recent  structural  studies  (25,  36-40)  propose,  on  the  basis  of nuclear  magnetic 
resonance (NMR)  data, that  dextrans B 1498S,  B 1355S4,  and B 1501S  are comb-like 
structures made up of a  linear backbone of [-3DGlcc~(1--~6)DGIca(1---~3)DGIcl-]n  with 
short side chains of one or more glucoses linked a(1--~6) to the 3-1inked glucoses of the 
main chain occurring about one every four or six [-3DGIca(1--)6)DGIcc~(1--*3)DGIcl-] 
units. If  the site is a partial cavity as hypothesized, the high reactivity of these dextrans 
might be ascribed to the unsubstituted [-6DGIcc~(1---*3)~DGIc-]  portion of the backbone 
repeat reacting in the groove portion of the site complementary to the subterminal 
DGlc.  However, it is also possible that the nonreducing terminal DGlca(1---~6) unit of 
the side chains of the three dextrans  might  be reacting in  the cavity-portion of the 
site.  In  both  instances  precipitation  would  be a  result  of multivalence.  All  of the 
branched oligosaccharides studied had DGIcc~(1---~4)  or mGlca(1---*3) side chains linked 
to  an  a(1---*6)  backbone  and  as  inhibitors  those  with  mGlc~(1---->4) branches  were 
somewhat better than those with DGlca(1--*3) branches. 
Thus it is quite surprising that CAL20 TEPC 1035 did not precipitate with dextrans 
B1254S[L] and B742L which contain DGlc branches linked a(1---~4) to long chains of 
a  DGlca(1--*6)-linked  backbone  (38),  thus  resembling  the  4-1inked  isomahosyl 
oligosaccharides  which  inhibited  quite  well.  Antiserum  895  (anti-panosyic~- 
(1---*4)DGIc~bNCS-BSA)  reacted well with its homologous antigen  and with dextrans 
having  different  proportions  of various  linkages  whereas  CAL20  TEPC1035  was 
precipitated only by dextrans B1355S4, B1498S, and B1501S although its combining 
site shows a  high specificity for the  tetrasaccharide  panosyl-oL(1--*4)DGlc.  The non- 
reactivity of these dextrans may be a result of their molecular configuration blocking 
access to the small combining site of CAL20 TEPC 1035.  This is consistent with the 
findings  that  the  ]sopanosylc~(1--*4)isopanose obtained  from  pullulan  was  a  good 
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other  hand  the  weak  cross  reactivity  of B1254S[~,]  and  B742L  with  the  c~(l---~3)- 
specific anti-dextrans J558, UPC 102, and MOPC 104E would be accounted for if the 
a(1----)4) branches could be accommodated in an a(l--)3)-specific site. This was indeed 
found to be the case with  anti-B1355S4  LAT2 (10);  this  antiserum  after  absorption 
with  B512  was  inhibited  by 44  C~-D-glucosylisomahohexaose and  4 a ~t-D-glucosyliso- 
mahotetraose  only slightly  less well  than  by 34 et-D-glucosylisomaltohexaose and  33 
a-D-glucosylisomaltotetraose.  The  failure  of the  panosyl-a(1---~4)DGicthNCS-BSA to 
precipitate  with CAL20 TEPC 1035 is surprising.  The antigen has only four glycosyl 
groups per molecule. It is possible that these are not distributed  in a manner allowing 
precipitation, or that more groups are necessary for precipitation, or that if interaction 
occurs the complexes are soluble or result  from steric effects. 
A  partial  cavity  type  site  complementary  to  at  least  a  terminal  nonreducing 
trisaccharide  unit  DGlca(1-*6)DGIct~(1--*4)DGIc- would  appear  to  account  satisfac- 
torily  for all  of the  inhibition  data  (Fig.  3).  Thus  panose  would  be  best  with  the 
terminal  nonreducing  oGica(1--*6)  moiety  held  in  three  dimensions  in  the  cavity 
subsite and contributing most of the binding energy (73% that of panose itself)  with 
the rest  of the site  being a  groove accessible  to internal  maltosyl linkages  (13).  The 
failure  of the  other  dextrans  to  cross-react  would  be  a  consequence  of their  very 
different  structures,  whereas  the  reactivity  of CAL20  TEPC1035  with  the  three 
dextrans  with  long chains of oGlco~(1--)6)DGlcot(1-~3)  would be accountable  for as 
either of the  two alternatives  presented  above.  It would also be consistent  with  the 
increased  inhibitory  potency of M6  and  M7  over M2  and  M3  being  ascribable  to 
bivalence  of  the  oligosaccharide.  If  the  NMR  data  on  the  three  dextrans  that 
precipitate  with  CAL20  TEPC1035  do  not  unequivocally  exclude  the  presence  of 
some  oGlco~(1-~6)DGlcc~(1--*3)  side  chains  on  the  comb-like  backbone,  2 this  would 
provide an additional  much better alternative because oGlct~(1--~6)oGlca(1-*3)oGlc 
is a  very good inhibitor and would appear to be reacting with the entire site but not 
fitting  as  well  as  panose.  Indeed  with  B1355S  from  methylation,  enzymatic  and 
immunochemical  studies  Torii  et  al.  (31)  have  proposed  an  alternative  tentative 
structure  with  chains  having  terminal  nonreducing  DGlct~(1---)6)DGlcoz(1-*3)DGlc 
units which would account for one of two specificities in rabbit antisera to B1355S as 
well  as  be  consistent  with  the  present  interpretation  for  the  reactivity  of CAL20 
TEPC 1035. 
It must be emphasized that the above interpretations  are made on the basis of the 
limited data available and assume that no oligosaccharides with ot(1---~6) and c~(1---~3) 
linkages  more  potent  than  panose  will  be  found.  Alternative  possibilities  might  be 
that the site is directed toward structures such as 
DGIca 1---~  3DGIct~ 1---~6DGlc  DGlca 1--~6DGIca 1---~  3 DGIc 
6  3 
1'  or  1' 
c~1  c~l 
oGlc  oGlc 
in which the essential  requirement  would be that the DGlc side chain be attached  to 
2 Note added in proof: Misaki et al. have recently proposed a structure consistent with the occurence of 
such side chains (Misaki, A., M. Torii, T. Sawai, and I. J. Goldstein. 1980. Structure of the dextran of 
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a disubstituted DGIc as was proposed (39) to account for higher activity of nigerotriose 
over nigerose with J558.  If one of these compounds proves to be more active than 
panose this would be consistent with the Ki  a data on methyl a-D-glucoside and would 
account for the failure of IM3q~CNS-BSA to precipitate. It would be highly desirable 
to study tetrasaccharides wtth these structures. 
Another  possibility  might  be that  the  site  is  entirely  specific  for  the  backbone 
requiring  a  tetra-  penta-  or  hexasaccharide  with  alternating  a(1--,6)  and  a(1--*3) 
linkages; this would make the site entirely groove-type and would not be consistent 
with the data on the high Ki  a of methyl a-n-glucoside as well as the binding data for 
the  cavity type site of W3129  (13,  15)  relative  to the  groove type of QUPC52.  It 
should be noted, however, that higher K a were found with antistreptococcal antibodies 
directed against internal sequences, e.g., groove-type sites of rhamnose with a(1--~2) 
and a(1---~3)  linkages.  Although  this  is attributable  to the  hydrophobic  interaction 
with the CHn group of C6 of rhamnose (41, 42), enough data are not as yet available 
to correlate the magnitudes of binding constants precisely with site structure. 
Should none of these alternatives prove to be correct and should panose remain as 
the  best  inhibitor,  the  possibility  of the  existence  of another  class  of dextrans  or 
polysaccharides  with  terminal  nonreducing  panosyl  moieties  than  those  currently 
known will have to be considered. It would also be of interest to study the antibody 
response of the CD mouse to one or more of the three dextrans with which CAL20 
TEPC1035  reacts to determine whether  induced  anti-a(1---~3)  dextran  sites behave 
like that of CAL20 TEPC 1035. 
It should  be remembered that  heteroclitic antibody formation (e.g., an antibody 
which  reacts  more  strongly  to  a  related  antigen  than  to  the  antigen  used  for 
immunization)  in the mouse has been described  (43);  in this instance the C57BL/6 
mouse immunized with  a  protein containing 4-hydroxy-3-nitrophenyl acetyl deter- 
minants produced antibody that reacted more strongly with derivatives in which an 
iodo- or a nitro-group was substituted on carbon 5 of the benzene ring than with the 
immunizing antigen;  this heteroclitic response was under genetic control.  It is con- 
ceivable that studies with B1355S might demonstrate a heteroclitic response. 
The unusual nature of the combining site of CAL20 TEPC 1035 make it desirable 
to  sequence  the  molecule  and  to  attempt  to  obtain  crystals  of an  Fab  fragment 
suitable for high-resolution x-ray crystallography. 
Summary 
The immunochemical specificity of the combining sites of murine myeloma protein 
CAL20 TEPC1035  was studied  by quantitative precipitin and precipitin inhibition 
assays. Myeloma protein CAL20 TEPCI035  precipitated with only three dextrans, 
B1355S4,  B1498S,  and  B1501S,  with  high proportions of a(1---~3)  linkages, but  not 
with any other dextrans, glycogen, and pullulan. Inhibition tests with various sugars 
show that the combining site of myeloma protein CAL20 TEPC 1035 is most comple- 
mentary  to  panose,  a  trisaccharide  DGlca(1-*6)vGlca(1---*4)oGlc.  Panose  was  3.3 
times more potent than  a  tetrasaccharide DGlca(1--~6)DGlca(1---~4)oGlcot(1--~4)DGlc 
and 8, 23, 42, >42 times more active than maltose, nigerose, isomaltose, and kojibiose, 
respectively. These findings were paralleled by their binding properties as determined 
by affinity electrophoresis. The association constants  (K  a) of these three dextrans to 
myeloma protein CAL20 TEPC1035 ranged from 3.8 X  10  a ml/g to 5.02 X  10  a ml/g. S.  SUGII,  E.  A.  KABAT, M.  SHAPIRO, AND M.  POTTER  179 
The association constam of inhibitor  (Ki  a) of panose was 8.19  ×  10  a M-k  Myeloma 
protein  CAL20 TEPC1035  is an antidextran  with specificity different  from those of 
other murine  myeloma antidextrans  and  from human  antidextrans  reported  previ- 
ously, and its combining site size is at  least  as large as a  trisaccharide.  The binding 
constant of methyl a-D-glucoside (7.2 ×  10  z) was 73% of that of panose and comparable 
to that of myeloma protein W3129  (9.4 ×  10  z) with a  cavity-type site and 600 times 
lower (1.6 X  10  °)  for QUPC52 with a  groove type site,  indicating that the terminal 
nonreducing residue is held in a  cavity. Inhibition  data with various a(1--*4)-linked 
oligosaccharides also indicate that the internal portions of these inhibitors may react 
directly with a  portion of the combining site.  These findings suggest that  myeloma 
antidextran CAL20 TEPC 1035 has a partial cavity-type combining site in which the 
terminal  nonreducing  DGIca(1--*6)  moiety  is  held  in  a  cavity with  the  other  two 
sugars  forming a  groove.  However,  oligosaccharides  with  one  or  more  alternating 
[--~3DGlcot(1-*6)DGIca(1--*3)DGIcI--*] units  with and without  terminal  nonreducing 
vGlca(1--*6)  or DGIca(1--*3)  side  chains  remain  to be tested  to determine  whether 
structures  known  to  be  present  in  the  three  dextrans  which  precipitate  CAL20 
TEPC1035 may not prove to be more active than panose. 
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